C4 Therapeutics Inc (NAS:CCCC)
$ 4.38 -0.43 (-8.94%) Market Cap: 301.37 Mil Enterprise Value: 142.48 Mil PE Ratio: 0 PB Ratio: 1.16 GF Score: 56/100

C4 Therapeutics Inc at Bank of America Precision Oncology Conference Transcript

Oct 03, 2022 / 01:50PM GMT
Release Date Price: $8.69 (-0.91%)
Chi Meng Fong
BofA Securities, Research Division - VP and Research Analyst

Hello, everyone. Welcome to the BofA Precision Oncology Conference. My name is Chi Fong, one of the biotech [EPC] of BofA. I'm joined by my colleague, Jason Gerberry, senior biotech analyst.

Here with us for the next fireside chat is C4 Therapeutics. For those who don't know, C4 is a clinical-stage biotech company focused on developing protein degraders for the treatment of cancers. I'm pleased to introduce Andrew Hirsch, CEO; and Adam Crystal, CMO from C4 Therapeutics.

Andrew and Adam, thanks so much for joining us at our fireside chat today.

Andrew J. Hirsch
C4 Therapeutics, Inc. - CEO, President & Director

Thanks for having us.

Questions & Answers

Chi Meng Fong
BofA Securities, Research Division - VP and Research Analyst

So Andrew, maybe to start off, can you talk about the company's broad philosophy on designing protein degraders? What are some of the key considerations for selecting a target to pursue

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot